Janus kinase inhibitors in the treatment of psoriatic arthritis
The article presents an analysis of literature data on the use of a new group of targeted synthetic disease-modifying antirheumatic drugs (DMARDs) Janus kinase (JAK) inhibitors – tofacitinib (TOFA) and upadacitinib (UPA) – in psoriatic arthritis (PsA). The results of randomized placebocontrolled cli...
Saved in:
| Main Authors: | E. Yu. Loginova, T. V. Korotaeva |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2022-02-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/1245 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The use of selective Janus kinase inhibitor upadacitinib in a patient with psoriatic arthritis (clinical observation)
by: Yu. A. Lushpaeva
Published: (2025-04-01) -
Clinical significance of Janus kinase inhibitors in the therapy of rheumatoid arthritis: achievements and prospects
by: V. I. Mazurov, et al.
Published: (2019-10-01) -
Janus kinase inhibitors in immunoinflammatory diseases: 10 years of clinical practice in rheumatology
by: E. L. Nasonov, et al.
Published: (2022-05-01) -
State-of-the-Art Evidence for Clinical Outcomes and Therapeutic Implications of Janus Kinase Inhibitors in Moderate-to-Severe Ulcerative Colitis: A Narrative Review
by: Yunseok Choi, et al.
Published: (2025-05-01) -
Efficacy and safety of Janus kinase inhibitors in the treatment of psoriasis and psoriatic arthritis: An analysis of evidence from 2014 to 2022
by: Jiao Wang, et al.
Published: (2025-02-01)